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OBJECTIVES: While information on the volume of
various drugs purchased by U.S. hospitals exists, infor-
mation on how hospitals actually utilize drugs is not
widely obtainable. We used inpatient transaction-level
data to investigate the association between patient char-
acteristics and treatment with selected anti-infective (AI)
drugs. We then applied this information to estimate AI
usage in a larger group of hospitals where no drug uti-
lization data were available. METHODS: We extracted
data for October 2000 through September 2001 from
Solucient’s Hospital Drug Utilization Database, which
contains patient-level demographic, clinical, and drug
information for 2.1 million inpatient discharges from 150
hospitals. Patients were classiﬁed into ﬁve clinical groups:
lower respiratory infection (LRI), septicemia, skin infec-
tion, urinary tract infection (UTI), and other. Separate
logistic regression models were ﬁtted for each group, with
patient characteristics as independent variables and use
of any of 20 common intravenous or oral AIs as the
outcome variable. We adjusted for principal diagnosis,
procedures, and interactions between principal and 
secondary diagnoses. Predictive accuracy was evaluated
using split-sample validation techniques. Coefﬁcients
from the regression models were then applied to records
of similar patients in Solucient’s Projected Inpatient 
Database, which contains 19 million hospital discharge
records annually but does not include drug data. We pro-
duced estimates of the probability of AI use for patients
in each clinical group at each hospital. RESULTS: Based
on split-sample methods, sensitivity ranged from 74.6%
for UTI to 90.9% for septicemia. Speciﬁcity ranged from
68.4% for LRI to 85.2% for the “other” category.
Percent correctly classiﬁed ranged from 74.7% for UTI
to 87.5% for septicemia. Interaction between principal
and secondary diagnosis codes was a strong predictor of
AI use. CONCLUSIONS: In inpatient data that lack
pharmaceutical information, use of selected anti-
infectives in these speciﬁc clinical groups can be predicted
with some accuracy based on patient characteristics.
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OBJECTIVE: To systematically review published eco-
nomic modeling studies directly comparing speciﬁc anti-
retroviral (ARV) drug treatment strategies. METHODS:
A systematic literature search using MEDLINE was con-
ducted of the English-language literature published
between 1995 and 2002 to capture modeling studies after
introduction of HAART using the following keywords:
AIDS, HIV, ARV, modeling, and costs. Manual searches
were also conducted of article bibliographies and other
relevant databases. Articles were excluded if they were
not direct drug comparisons (general HAART vs. no
HAART; PI class vs. NNRTI class). Factors including
model approaches, use of probabilistic sensitivity analy-
sis, and target audiences and journals were assessed.
RESULTS: Of >400 abstracts screened, only 38 articles
were identiﬁed as economic models of ARV therapy and
were reviewed in detail. Ten of these studies (6 US; 2 UK;
2 multi-country) directly compared speciﬁc ARV treat-
ments. Of these, 5 assessed cost-effectiveness over 
timeframes of 20–40 years, of which 2 also evaluated
cost-utility. The other 5 presented cost-consequence or
cost analysis with timeframes of 1 year in 4 of the studies.
Six studies compared zidovudine monotherapy to speciﬁc
combinations. Four studies used Markov modeling tech-
niques, while 3 used Monte Carlo simulation to test
uncertainty. Target audiences were typically the payer,
with one of the articles speciﬁcally tailored to a state
AIDS Drug Assistance Program perspective. Seven of the
studies were published in health economic or managed
care journals, and 3 published in therapeutic area-speciﬁc,
clinical journals. CONCLUSIONS: Economic models
comparing speciﬁc ARV treatments only represent ~25%
of published modeling studies in HIV/AIDS. Although
antiretroviral (ARV) therapies have been broadly reim-
bursed in the past, as more treatment options become
available, payers may increasingly require economic com-
parison of speciﬁc ARV drug treatment strategies. Until
recently, there has been widespread reimbursement of
HAART, which may explain the small number of head-
to-head economic modeling studies.
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OBJECTIVES: Pneumococcal disease is the leading cause
of bacterial infection in children, resulting in signiﬁcant
morbidity and mortality. In Canada, a heptavalent con-
jugate vaccine (PCV-7) aimed at preventing pneumococ-
cal diseases in children has been recommended by the
National Advisory Committee on Immunization. The
objective of this study was to identify value determinants,
both quantitative and qualitative, that contribute to the
societal beneﬁt of implementing a universal PCV-7
program. METHODS: Incidence rates and societal costs
were estimated for clinical and economic outcomes in
Canadian children less than ﬁve years of age: meningitis,
pneumonia, bacteremia, otitis media, and myringotomy.
These data were obtained primarily from a systematic
review of the literature on pneumococcal disease and
vaccine cost-beneﬁt using an OVID interface and included
the following databases: Pre-Medline, Medline and
EMBASE. The search was narrowed to studies of effec-
